About Careers MedBlog Contact us

Colorectal Cancer Incidence, Death, and All-Cause Mortality Lowered by Regular Primary Care Visits

by Kathy Jones on October 1, 2013 at 8:44 PM
Font : A-A+

 Colorectal Cancer Incidence, Death, and All-Cause Mortality Lowered by Regular Primary Care Visits

New research indicates that regular primary care visits lower colorectal cancer incidence, death, and all-cause mortality.


Medicare beneficiaries with more visits to their primary care physician (PCP) have lower colorectal cancer (CRC) incidence, CRC-specific mortality, and all-cause mortality. CRC is preventable with appropriate screening and polypectomy, yet many of the people who could benefit from it either are not screened, or do not start screening early enough. Recommendations from physicians are the strongest predictors of adherence to CRC screening guidelines. Researchers hypothesized that patients with few or no visits to a PCP would have higher CRC incidence and mortality due to never having been screened or having a polypectomy. Medicare records for patients aged 67-85 who were diagnosed with CRC between 1994 and 2004 in U.S. Surveillance, Epidemiology, and End Results (SEER) regions were compared with health records of control patients to examine the association of utilization of PCPs with CRC incidence and actual mortality. The researchers found that the likelihood of CRC diagnosis, CRC-specific death, and all-cause mortality decreased with increasing primary care visits. These rates were also lower for patients frequently seeing any type of provider. The authors suggest that increasing and promoting access to primary care for Medicare beneficiaries may reduce the national burden of CRC. Editorialists agree that access to care is paramount. However, they caution that other factors, such as patient non-adherence to scheduled care, may affect CRC screening rates and subsequent outcomes. They also point out that "healthy user" bias is a shortcoming of observational studies.

Note: For an embargoed PDF, please contact Megan Hanks or Angela Collom. The lead author can be reached through Jennifer Forbes at jenn.forbes@rwjms.rutgers.edu or 732-235-6356.

2. Patient outcomes are not affected by early discharge from busy ICUs

Doctors in strained ICUs are more likely to make high-value care decisions

Physicians in resource-strained intensive care units (ICUs) are likely to discharge patients more efficiently without negatively affecting outcomes. Health care costs in the U.S. are likely to increase strain on ICU resources. Strain on ICU capacity may influence care providers to discharge patients as soon as possible to open beds, and communication may suffer during patient handoffs. Researchers reviewed heath records for 200,730 adults discharged from 155 ICUs in the U.S. to determine how ICU capacity strain on day of patient discharge affects ICU length-of-stay and post-ICU discharge outcomes. ICU capacity was measured by ICU census, number of new admissions, and average number of patients. The researchers found that when ICUs were busy, patients stayed for a shorter time and were somewhat more likely to be readmitted to the ICU. However, there were no increases in patient mortality rates, no greater overall length of hospital stay, and no greater rate of hospital readmission within 30 days of hospital discharge. The authors suggest that physicians are more likely to practice high-value care, efficiently discharging those patients who do not actually require ICU treatment.

Note: For an embargoed PDF, please contact Megan Hanks or Angela Collom. Lead author Dr. Jason Wagner can be contacted through stephen.graff@uphs.upenn.edu or 215-349-5653.

3. Medicare Advantage plans underreport high-risk prescribing practices

Under the Patient Protection and Affordable Care Act, the Centers for Medicare & Medicaid Services (CMS) are required to publicly report quality and performance measures so that providers and patients are fully informed about cost and quality of care. However, the accuracy of these reports is not known. Medicare Advantage plans report clinical performance using Healthcare Effectiveness Data Information Set (HEDIS) quality indicators. Researchers reviewed 172 Medicare Advantage Plans to compare reported HEDIS rates of high-risk prescribing (prescribing drugs that should be avoided in elderly patients) to rates calculated using Medicare Part D claims. They found that, on average, plans underreported high-risk prescribing by 5.8 percentage points. When ranking plans according to their calculated versus reported performance, plans with the most accurate reporting had the greatest penalty and those with the least accurate reporting had the greatest gain. The researchers also found that the rate of high-risk prescribing was the same for Medicare Advantage and Medicare fee-for-service beneficiaries. However, policymakers evaluating plan-reported rates would erroneously conclude that Medicare Advantage program has relative rates of high-risk prescribing that are approximately 20 percent lower than fee-for-service. This analysis suggests that reported performance measures should be regularly audited to ensure accuracy.

Note: For embargoed PDFs please contact Megan Hanks or Angela Collom. For an interview with an author, please contact David Orenstein at 401-863-1862 or david_orenstein@brown.edu.

Source: Eurekalert


Recommended Reading

Latest Cancer News

 Myelofibrosis: New Drugs to Revolutionize Treatment
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
 Blood Vessels Can Kill Cancer Cells and Stop Breast Cancer Spread
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
 Weed Killer Agent Orange May Increase the Risk of Blood Cancer Among Veterans
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Two Years: Optimal Duration of Immunotherapy in Advanced Lung Cancer
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable
Hope for Lethal Brain Tumors: Targeted Therapy Delays Glioma Progression
A ray of hope for glioma patients as targeted therapy boosts treatment duration.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Colorectal Cancer Incidence, Death, and All-Cause Mortality Lowered by Regular Primary Care Visits Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests